AbbVie (NYSE:ABBV) Downgraded by Wall Street Zen to Buy

Wall Street Zen cut shares of AbbVie (NYSE:ABBV) from a strong-buy rating to a buy rating in a report released on Saturday.

ABBV has been the topic of a number of other reports. BMO Capital Markets raised their price target on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. JPMorgan Chase & Co. raised their target price on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. UBS Group upped their price target on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Scotiabank started coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock. Finally, Evercore ISI boosted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Stock Performance

Shares of ABBV stock opened at $229.26 on Friday. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock’s fifty day moving average is $226.69 and its two-hundred day moving average is $213.94. The firm has a market capitalization of $405.19 billion, a P/E ratio of 173.68, a PEG ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s payout ratio is 496.97%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after acquiring an additional 448,554 shares during the last quarter. Geode Capital Management LLC raised its position in shares of AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after buying an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after acquiring an additional 1,517,222 shares during the last quarter. Norges Bank acquired a new position in AbbVie in the 2nd quarter valued at $4,288,200,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of AbbVie by 5.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 12,771,854 shares of the company’s stock worth $2,675,959,000 after purchasing an additional 713,148 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Signed a licensing/option deal with Zelgen around a T‑cell engager worth up to $1.1B, strengthening AbbVie’s oncology pipeline and potential future revenue streams. New year sees Abbvie, Zelgen in $1.1B T-cell engager deal
• Positive Sentiment: Zelgen Pharma confirmed a licensing option agreement with AbbVie, reiterating the near-term deal structure that adds option value to AbbVie’s immuno‑oncology portfolio. Zelgen Pharma inks licensing option agreement with AbbVie
• Positive Sentiment: AbbVie (and peers) are acquiring/licensing clinical‑stage cancer assets in multiple deals, accelerating near‑term pipeline growth without full internal development cost. AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals
• Positive Sentiment: Neuroscience franchise (Botox, Vraylar, migraine drugs) now contributes >17% of revenue and is fueling double‑digit sales growth, supporting AbbVie’s top line even as other areas reset. Here’s How AbbVie’s Neuroscience Portfolio Is Aiding Top-line Growth
• Positive Sentiment: Partner performance (Ironwood’s beat tied to AbbVie‑partnered Linzess) highlights durable royalties/partner cash flow from legacy assets. Ironwood beats on 2026 outlook thanks to AbbVie-partnered Linzess
• Positive Sentiment: Wall Street Zen changed coverage to a Buy, an analyst upgrade that can support near‑term investor demand. AbbVie (NYSE:ABBV) Cut to Buy at Wall Street Zen
• Neutral Sentiment: Analysts and previews expect AbbVie’s upcoming Q4 report to show double‑digit EPS growth; the print will be a key near‑term catalyst. What to Expect From AbbVie’s Next Quarterly Earnings Report
• Neutral Sentiment: Additional earnings previews reiterate expectations for strong bottom‑line growth, making the earnings release the primary short‑term focus. What to Expect From AbbVie’s Next Quarterly Earnings Report
• Neutral Sentiment: Balanced analyst commentary: some see an attractive setup for 2026 given growth and dividends, but note company risks. AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026
• Negative Sentiment: Valuation concerns: analysts note recent rally but argue ABBV may not be a bargain given a high P/E and limited margin for upside absent strong surprises. AbbVie’s Rally Looks Convincing — But The Stock Is Not A Bargain
• Negative Sentiment: Macro/rate risk: commentary to dividend investors warns that shifting Treasury issuance and shorter maturities make dividend stocks more sensitive to Fed policy — a potential headwind for high‑yield pharma names. My Most Important Warning To Dividend Investors For 2026

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.